Selank and Semax: Russian Clinical Trial Evidence: A Research Synthesis

To understand Selank and Semax, the research context that produced them matters. Soviet and post-Soviet Russia developed a distinctive tradition of peptide neuropsychopharmacology that diverged significantly from Western drug development pathways. While Western research focused predominantly on small-molecule drugs with large-scale randomised controlled trials, Soviet research invested heavily in synthetic peptide analogues of endogenous regulatory molecules, evaluating them in smaller cohort trials under the Russian Ministry of Health's approval framework rather than FDA or EMA standards.

This produced a literature that is:

• Predominantly published in Russian-language journals (Eksperimental'naya i Klinicheskaya Farmakologiya, Zhurnal Nevrologii i Psikhiatrii, and others)
• Partially indexed in international databases, some papers appear in PubMed in translated or abstract form; many do not
• Based on smaller sample sizes and open-label designs by Western RCT standards
• Often conducted by or in collaboration with the originating research group rather than independent replication teams

This does not make the evidence valueless, it means it must be evaluated differently than a Phase 3 FDA submission. Both Selank and Semax are approved and used clinically in Russia and Ukraine, reflecting regulatory judgement under a different evidentiary framework. For Australian and international researchers, this literature represents the primary, and often only, human data available for these compounds.

Both Selank and Semax were developed at the Institute of Molecular Genetics (IMGRAS) of the Russian Academy of Sciences in Moscow, by the laboratory of Professor Nikolai Mjasoedov and colleagues including Professor Nikolai Seredenin. The institute's peptide pharmacology programme, active since the 1970s, focused on synthetic analogues of endogenous regulatory peptides, immunomodulators, neuropeptides, and stress-response mediators.

The design strategy was to take short functional sequences from known bioactive peptides and modify them for metabolic stability. Both Selank and Semax share a C-terminal Pro-Gly-Pro (PGP) extension, a tripeptide addition that resists proteolytic degradation, extending functional half-life compared to the parent sequences without altering receptor interactions.

• Selank (TKPRPGP), derived from tuftsin, an endogenous tetrapeptide fragment of IgG with immunomodulatory and anxiolytic properties. The tuftsin core sequence TKPR is extended with PGP for stability. Registered in Russia as an anxiolytic.
• Semax (MEHFPGP), derived from the ACTH(4–7) sequence (Met-Glu-His-Phe), the fragment of adrenocorticotropic hormone responsible for neurotrophic and neuroprotective effects but lacking corticotropic activity. The PGP extension stabilises the core. Registered in Russia for ischaemic stroke and cognitive disorders.

The shared laboratory origin and shared PGP stabilisation strategy means the two compounds are often studied together, though their pharmacological profiles diverge substantially.

Selank's primary clinical evidence concerns its anxiolytic properties in generalised anxiety disorder (GAD) and related conditions. The most frequently cited trials compare Selank to medazepam, a benzodiazepine used as an active comparator in Russian clinical psychiatry.

Anxiolytic trials (GAD): Clinical studies at Russian psychiatric research centres evaluated Selank in GAD patients using the Hamilton Anxiety Rating Scale (HAM-A) as the primary outcome measure. Key findings across these trials:

• Selank produced clinically significant reductions in HAM-A scores over 14-day treatment periods
• Anxiolytic effect was comparable to medazepam in head-to-head comparison cohorts
• Selank did not produce sedation, cognitive impairment, or dependence signals associated with benzodiazepine treatment, a key mechanistic distinction
• Secondary cognitive outcome measures (attention, memory consolidation) improved in Selank-treated subjects, in contrast to medazepam where cognitive measures typically decline

Immunomodulatory studies: Reflecting its tuftsin-derived structure, Selank has been investigated for immune function effects. Clinical and preclinical studies document modulation of cytokine expression, effects on IL-6 and TNF-α, and changes in T-cell subpopulation ratios. The immunomodulatory profile is considered secondary to the anxiolytic application but carries independent research interest, particularly in studies examining the gut-brain-immune axis.

Enkephalinase inhibition: A consistent mechanistic finding is Selank's inhibition of enkephalin-degrading metalloproteinases, specifically enzymes that cleave met-enkephalin and leu-enkephalin. By stabilising endogenous enkephalins, Selank elevates endogenous opioid peptide activity in limbic regions. This is proposed as a primary contributor to its anxiolytic profile and mechanistically distinguishes Selank from both benzodiazepine and SSRI mechanisms.

BDNF upregulation: Multiple preclinical and some clinical studies have documented Selank-associated increases in BDNF expression in hippocampal and cortical tissue, a finding shared with Semax and proposed to underlie the cognitive-enhancing secondary effects observed in anxiolytic trials.

Semax's clinical evidence base spans three primary application areas: ischaemic stroke recovery, cognitive and attentional disorders, and optic nerve pathology.

Ischaemic stroke trials: Semax has the most substantial clinical evidence in acute and subacute ischaemic stroke. Russian clinical trials, published primarily in neurology journals from the 1990s through 2010s, evaluated intranasal Semax in stroke patients at doses typically around 0.1% solution (approximately 0.9 mg/dose) administered over 5–10 days. Key findings:

• Improvements in neurological deficit scores (Scandinavian Stroke Scale, NIHSS equivalents) compared to control groups
• Reductions in infarct size in imaging sub-studies
• Improved cognitive and functional recovery at 30-day and 90-day follow-up
• Neuroprotective mechanism attributed to BDNF and NGF upregulation in peri-infarct tissue, attenuation of excitotoxicity, and anti-inflammatory CNS effects

Cognitive and attention studies: Beyond stroke, Semax has been investigated in cognitive impairment, attentional presentations, and healthy subjects under cognitive load. Studies in children with attentional disorders showed improvements in attention and working memory. Studies in healthy adult subjects demonstrated enhanced performance on sustained attention tasks. Trials in this area are generally smaller (20–60 subjects) and open-label.

Optic nerve and visual system research: A distinctive application with a published Russian evidence base is Semax in progressive myopia and optic nerve atrophy. Russian ophthalmological trials evaluated intranasal Semax in patients with optic nerve damage, reporting improvements in visual acuity and nerve function metrics. This reflects Semax's NGF upregulation effects on retinal ganglion cells and the optic nerve, a CNS pathway with known NGF dependence.

BDNF and NGF biomarker studies: A methodological strength of several Russian Semax trials is the inclusion of peripheral blood BDNF and NGF measurements at baseline and post-treatment, documenting significant elevations following Semax administration. This provides direct mechanistic correlates of the clinical outcomes and is the most readily verifiable finding in the clinical literature.

Across both compounds, the mechanistic evidence is more consistent and independently replicated than the clinical trial evidence. Western preclinical research has confirmed several key mechanisms:

The mechanistic evidence is broadly consistent with the clinical claims. Where Western replication exists, it supports the proposed mechanisms, the gap is in independent large-scale human clinical trials, not in the fundamental pharmacology.

Researchers approaching this literature need to apply appropriate critical appraisal. The limitations define the confidence level that is epistemically appropriate:

Sample sizes: Most Russian clinical trials enrolled 30–120 subjects per arm, adequate for detecting large effect sizes but underpowered for modest effects or rare adverse events. Modern Phase 3 trials typically enrol thousands.

Publication accessibility: The majority of clinical data is published in Russian-language journals not indexed in PubMed or available only in abstract form. Peer review standards and reporting quality are harder to assess without full-text access. Several key papers exist only as Russian-language publications with no English translation.

Trial design: Open-label designs predominate in the older literature. Double-blind placebo-controlled trials exist but the proportion meeting modern reporting standards (CONSORT checklist, pre-registration, ITT analysis) is lower than Western Phase 2/3 norms.

Independence: Many trials were conducted by or in collaboration with the originating research group at IMGRAS. Independent replication by unaffiliated teams is limited.

Regulatory non-equivalence: Russian drug approval uses different evidentiary thresholds than FDA, EMA, or TGA approval. Approval in Russia does not imply a compound would satisfy Western regulatory requirements. TGA approval would require independent Phase 2/3 data submitted through the Australian regulatory framework.

Several areas show convergence between the Russian clinical literature and Western independent research:

BDNF as a mechanistic anchor: BDNF upregulation by both Selank and Semax is the most consistently replicated finding across research groups and publication traditions. BDNF's role in synaptic plasticity, anxiety, depression, and neuroprotection is well-established in Western neuroscience, and the Selank/Semax-BDNF connection is mechanistically coherent with both compounds' clinical profiles.

Neuroprotection in ischaemia: The neuroprotective effects of Semax in rodent ischaemia models have been reproduced in Western preclinical research. Focal cerebral ischaemia, global ischaemia, and hypoxia-reoxygenation models have shown Semax-associated reductions in neuronal death and improved functional outcomes, supporting the Russian stroke trial findings at the mechanistic level.

Anxiolytic mechanism without dependence: Selank's anxiolytic effects without sedation or benzodiazepine-type dependence is mechanistically explicable through its non-GABA-A direct binding profile. Western animal studies of enkephalin stabilisation and GABAergic potentiation reproduce this pharmacological signature. The compound is genuinely mechanistically distinct from benzodiazepines.

Intranasal CNS delivery: Both compounds are typically delivered intranasally in Russian clinical studies, exploiting olfactory nerve pathways for direct CNS access. This delivery route has been validated in Western pharmacokinetic research for short peptides, the nasal mucosa–to–olfactory nerve–to–brain pathway is a legitimate route for small peptide CNS penetration and is not unique to Russian research.

For researchers outside the Russian literature, the evidence base provides:

Mechanistic hypotheses with preclinical support: The BDNF/NGF upregulation, enkephalinase inhibition, GABAergic potentiation, and neuroprotection mechanisms are appropriate starting hypotheses for in vitro and preclinical research. They are supported by both Russian and Western preclinical data and provide coherent rationale for protocol design.

Dosing reference from clinical literature: Russian clinical trials used intranasal delivery at 0.1% concentration (Semax), delivering approximately 0.9 mg per dose. Subcutaneous animal model protocols range from 0.5–5 mg/kg. These are starting reference points for preclinical protocol design, with appropriate model-specific adjustment.

High-value research gaps: The lack of Western independent clinical trials represents a genuine academic opportunity: (1) Selank in Western GAD populations with modern double-blind design; (2) Semax in Western stroke cohorts with contemporary neuroimaging endpoints; (3) both compounds in human biomarker studies (BDNF, NGF, cytokines) under controlled conditions. Well-designed mechanistic studies from non-Russian groups would be genuinely novel contributions to the literature.

OzPeps stocks research-grade Selank 10mg → and Semax 10mg → for laboratory research. See also the individual guides: Selank research guide → | Semax research guide →

Selank and Semax are supplied by OzPeps for in vitro and preclinical laboratory research use only. They are not TGA-approved for therapeutic use in Australia and are not intended for human or animal consumption. Clinical trial data cited reflects research conducted under Russian regulatory standards, which differ from TGA, FDA, and EMA frameworks. Researchers are responsible for compliance with all applicable regulations.